Bimal Shah
Direktor/Vorstandsmitglied bei ANEBULO PHARMACEUTICALS, INC.
Aktive Positionen von Bimal Shah
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 05.10.2023 | - |
| Independent Dir/Board Member | 05.10.2023 | - | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Finanzdirektor/CFO | 05.09.2012 | - |
| Treasurer | 05.09.2012 | - |
Karriereverlauf von Bimal Shah
Ehemalige bekannte Positionen von Bimal Shah
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.06.2010 | 01.01.2021 |
Ausbildung von Bimal Shah
| Stanford University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 1 |
| Director of Finance/CFO | 1 |
| Treasurer | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Börse
- Insiders
- Bimal Shah
- Erfahrung
